This program was recorded before the July 2, 2024 FDA approval of donanemab for Alzheimer’s disease treatment. Donanemab is an amyloid beta-directed antibody that should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population studied in clinical trials.
FACULTY
Manisha Parulekar, MD, FACP, AGSF, CMD
Chief, Division of Geriatrics
Co-director, Center for Memory Loss and Brain Health
Hackensack University Medical Center
Associate Professor, Hackensack Meridian School of Medicine
Hackensack, NJ
FEATURING
Karen and Brian
Wayne, NJ
PROGRAM OVERVIEW
This educational activity is designed to provide clinicians who manage patients with Alzheimer’s disease with current information on diagnosis and management, including the impact of the disease on caregivers.
TARGET AUDIENCE
This activity is designed to meet the educational needs of healthcare providers involved in the diagnosis and continued care of patients with Alzheimer’s disease, including neurologists, geriatricians, psychiatrists, primary care physicians, nurses, and other multidisciplinary team members.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement shared decision-making (SDM) approaches to facilitate diagnosis and optimize management
- Implement strategies to overcome barriers to timely diagnosis of Alzheimer’s disease, addressing stigma, applying quantitative assessments, and integrating neuroimaging as well as specialty referral in clinical assessment
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Manisha Parulekar, MD | Dr. Parulekar has nothing to disclose. |
| Karen (caregiver) and Brian (patient) | Have nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Dominique Barton, BSN, has nothing to disclose.
- Michael Milano, MD, discloses Up-To-Date royalties from Wolters Kluwer.
- Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 17, 2024
EXPIRATION DATE: June 17, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
This program was recorded before the July 2, 2024 FDA approval of donanemab for Alzheimer’s disease treatment. Donanemab is an amyloid beta-directed antibody that should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population studied in clinical trials.
FACULTY
Manisha Parulekar, MD, FACP, AGSF, CMD
Chief, Division of Geriatrics
Co-director, Center for Memory Loss and Brain Health
Hackensack University Medical Center
Associate Professor, Hackensack Meridian School of Medicine
Hackensack, NJ
FEATURING
Michele and Marie
Teaneck, NJ
PROGRAM OVERVIEW
This educational activity is designed to provide clinicians who manage patients with Alzheimer’s disease with current information on diagnosis and management, including the impact of the disease on caregivers.
TARGET AUDIENCE
This activity is designed to meet the educational needs of healthcare providers involved in the diagnosis and continued care of patients with Alzheimer’s disease, including neurologists, geriatricians, psychiatrists, primary care physicians, nurses, and other multidisciplinary team members.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement shared decision-making (SDM) approaches to facilitate diagnosis and optimize management
- Implement strategies to overcome barriers to timely diagnosis of Alzheimer’s disease, addressing stigma, applying quantitative assessments, and integrating neuroimaging as well as specialty referral in clinical assessment
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Manisha Parulekar, MD | Dr. Parulekar has nothing to disclose. |
| Michele and Marie | Have nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- Michael Milano, MD, discloses Up-To-Date royalties from Wolters Kluwer.
- Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: July 17, 2024
EXPIRATION DATE: July 17, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
